Influenza

Sabin Vaccine Institute Issues Statement on New Universal Flu Vaccine Development Grand Challenge

Retrieved on: 
Friday, April 27, 2018
RTT, Medicine, Microbiology, Vaccines, Influenza vaccines, Vaccination, Virology, Universal flu vaccine, Clinical medicine, Influenza, Influenza research, BiondVax

The Sabin Vaccine Institute has 25 years of experience catalyzing vaccine innovation through collaboration and partnerships.

Key Points: 
  • The Sabin Vaccine Institute has 25 years of experience catalyzing vaccine innovation through collaboration and partnerships.
  • "Alongside independent efforts such as the Grand Challenge, Sabin has embarked on a three-year initiative to help move the world closer to ending the threat of flu.
  • Our work will focus on fosteringinnovative approaches from diverse disciplines to accelerate the development of a universal flu vaccine.
  • Learn more about Ending the Pandemic Threat: A Grand Challenge for Universal Influenza Vaccine Development
    The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation.

Influenza Market, 2022 - Vaccines, Therapeutics and Diagnostics

Retrieved on: 
Wednesday, April 25, 2018
RTT, Medicine, Vaccines, Microbiology, Influenza vaccine, Influenza, Market, Health

The "The Global Influenza Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Global Influenza Market" report has been added to ResearchAndMarkets.com's offering.
  • This report is designed to be a helpful business tool that provides a thorough evaluation of the market for influenza vaccines, therapeutics and diagnostics.
  • The geographic scope of this study is global, with emphasis on U.S. and European data.
  • The report identifies markets in general segments: Vaccines, Therapeutics and Diagnostics.

Chisum Independent School District Incorporates Electrostatic Sprayer System to Help Protect Students, Teachers and the Local Community

Retrieved on: 
Tuesday, April 24, 2018
Medicine, Microbiology, Hygiene, RTT, Veterinary medicine, Flu season, Influenza, Seasonality, Influenza A virus subtype H1N1, Clorox, Virus, Chisum Independent School District

PARIS, Texas, April 24, 2018 /PRNewswire/ -- Chisum Independent School District is proud to announce the addition of the Clorox Total 360 System to our cleaning and disinfection tool belt.

Key Points: 
  • PARIS, Texas, April 24, 2018 /PRNewswire/ -- Chisum Independent School District is proud to announce the addition of the Clorox Total 360 System to our cleaning and disinfection tool belt.
  • The school district proactively invested in three systems to divide across our high school, middle school and elementary school to optimize disinfection protocols and help expel illness-causing germs and viruses to further safeguard our academic environment.
  • This flu season hit schools, including those in the Texas area, hard resulting in high rates of absenteeism and numerous school closures.
  • School districts are often the hardest hit by outbreaks with an estimated 38 million school days lost each year to influenza alone.

Mesa Biotech to Demonstrate New Molecular POC Testing Platform at the European Congress of Clinical Microbiology and Infectious Diseases

Retrieved on: 
Wednesday, April 18, 2018
Biology, Medicine, Pathology, Molecular biology, Laboratory techniques, Polymerase chain reaction, Amplifiers, Biotechnology, Infectious disease, Influenza, Medical microbiology, Medical diagnosis

SAN DIEGO, April 18, 2018 /PRNewswire/ -- Mesa Biotech Inc., a privately-held, molecular diagnostic company that has developed an affordable PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC) infectious disease diagnosis, today announced it will demonstrate its novel Accula Flu A/Flu B test at the 28th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

Key Points: 
  • SAN DIEGO, April 18, 2018 /PRNewswire/ -- Mesa Biotech Inc., a privately-held, molecular diagnostic company that has developed an affordable PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC) infectious disease diagnosis, today announced it will demonstrate its novel Accula Flu A/Flu B test at the 28th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
  • Diagnosis of influenza is difficult because initial symptoms can be similar to other upper respiratory virus infections.
  • The patented Accula system enables healthcare professionals to access actionable, laboratory-quality results at the POC with greater sensitivity and specificity than current infectious disease rapid immunodiagnostic tests.
  • Mesa Biotech designs, develops, manufactures and commercializes next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the point-of-care (POC).